Iovance Biotherapeutics, Inc. (IOVA)
NASDAQ: IOVA · Real-Time Price · USD
3.360
+0.170 (5.33%)
At close: Apr 24, 2025, 4:00 PM
3.350
-0.010 (-0.30%)
After-hours: Apr 24, 2025, 6:03 PM EDT
Iovance Biotherapeutics Stock Forecast
IOVA's stock price has decreased by -71.67% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 9 analysts with 12-month price forecasts for Iovance Biotherapeutics stock have an average target of 18.22, with a low estimate of 5.00 and a high estimate of 32. The average target predicts an increase of 442.26% from the current stock price of 3.36.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Iovance Biotherapeutics stock from 9 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 4 | 5 | 5 |
| Buy | 3 | 3 | 3 | 4 | 2 | 3 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 9 | 9 | 8 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $18 → $16 | Strong Buy | Maintains | $18 → $16 | +376.19% | Apr 17, 2025 |
| Barclays | Barclays | Buy Maintains $22 → $5 | Buy | Maintains | $22 → $5 | +48.81% | Apr 14, 2025 |
| Truist Securities | Truist Securities | Strong Buy Maintains $25 → $15 | Strong Buy | Maintains | $25 → $15 | +346.43% | Mar 3, 2025 |
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $22 → $19 | Strong Buy | Maintains | $22 → $19 | +465.48% | Mar 3, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $34 → $30 | Strong Buy | Maintains | $34 → $30 | +792.86% | Mar 3, 2025 |
Financial Forecast
Revenue This Year
463.01M
from 164.07M
Increased by 182.20%
Revenue Next Year
750.54M
from 463.01M
Increased by 62.10%
EPS This Year
-0.80
from -1.28
EPS Next Year
-0.33
from -0.80
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 495.3M | 972.4M | 1.4B | ||
| Avg | 463.0M | 750.5M | 1.0B | ||
| Low | 424.1M | 505.0M | 557.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 201.9% | 110.0% | 91.9% | ||
| Avg | 182.2% | 62.1% | 35.6% | ||
| Low | 158.5% | 9.1% | -25.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.64 | 0.02 | 1.05 | ||
| Avg | -0.80 | -0.33 | 0.35 | ||
| Low | -0.93 | -0.65 | -0.08 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.